Search

everythinglearnresearchcommunity

for

Search:↓

A 35-year-old male uses topical minoxidil, spironolactone, and microneedling for hair loss, with spironolactone prescribed based on a DNA test indicating poor response to finasteride and dutasteride. Despite concerns about the test's validity and spironolactone's side effects, he reports stable or improved hair condition and no low testosterone symptoms.

New hair loss treatments, including Breezula, VDPHL01, and PP405, are nearing Phase 3 trials, offering hope for effective solutions. Current treatments like finasteride and minoxidil remain effective, but early intervention is crucial.

A user discusses their rapidly receding hairline and a prescribed topical solution containing 7% Minoxidil, 0.1% Finasteride, and 3% biotinoyl tripeptide. The solution is a custom compound from their dermatologist, costing $50 for a one-month supply.

Veradermics has a market cap over a billion dollars, comparable to Cosmo pharmaceutical. Users discuss using Kintor's Pirylutamide for hair loss.

The conversation discusses whether to take oral minoxidil in a split dose or a single dose at night. Users suggest that taking a single 10mg dose at night is simpler, while splitting may help minimize side effects.

Triple Hair Inc. developed a new topical treatment, TH07, combining Finasteride, Latanoprost, and Minoxidil for androgenic alopecia. Users discussed its effectiveness compared to other treatments and shared their own product combinations.

Oral minoxidil is considered more convenient and effective for some users, with positive results reported, but concerns about side effects and availability persist. Finasteride remains a standard treatment, while some users explore combinations with other treatments like dutasteride and laser devices.

The user started taking oral 0.5 mg dutasteride and 2.5 mg minoxidil daily since July 9. After about three months, they report positive progress in hair regrowth, with others agreeing it looks good.

Amplifica has not provided updates on SCUBE3 and AMP-303, raising concerns about their trial outcomes. Users also mention other treatments like Minoxidil, finasteride, RU58841, PP405, and ET-03.

The user experienced significant hair regrowth using topical finasteride/minoxidil and oral minoxidil/dutasteride, with some mild side effects that diminished over time. They plan to add microneedling to their regimen and have seen hair shedding cycles every six months, followed by thicker regrowth.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

After 8 months of using topical finasteride, hair miniaturization continues, raising concerns about its effectiveness. Microneedling is suggested as a possible complementary treatment.

The user is using RU58841, Minoxidil, and weekly microneedling for hair loss, having stopped finasteride due to side effects like low libido and depression. They are considering dutasteride as an alternative but are cautious due to past experiences with DHT blockers.

The user experienced significant hair regrowth using dutasteride 0.5 mg daily, 5% topical minoxidil twice a day, and microneedling over several months. They also used ketoconazole shampoo and rosemary oil, reporting some side effects but overall positive results.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

Oral minoxidil is considered more convenient and effective than topical or sublingual forms, with users reporting positive results and minimal side effects. Some users experience side effects with oral minoxidil and opt for sublingual or topical methods instead.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

The user experienced significant hair regrowth using a topical solution of finasteride and minoxidil, applied nightly with a dropper. They reported no side effects and emphasized the importance of consistency in treatment.

The user experienced significant hair regrowth after 7 months using topical minoxidil once a day and 0.5mg dutasteride every other day, with noticeable results in the last two to three months. They reported no side effects and did not use dermarolling.

The user reports noticeable hair growth progress after three months using topical Minoxidil, oral Finasteride, microneedling, and Vitamin D. Encouragement and additional advice, like using keto shampoo, are given by others.

The user is trying a new hair loss treatment combining 1.25 mg oral minoxidil with a daily topical solution containing hydrocortisone, tretinoin, 8% minoxidil, and 0.025% finasteride. They aim to maintain their current hair before considering a hair transplant in Istanbul.

Delayed release oral minoxidil is seen as a promising advancement for hair loss treatment, offering safer, higher doses and more consistent hair follicle stimulation compared to current options. However, it is not expected to replace finasteride or dutasteride, as it does not prevent androgenetic alopecia.

The conversation discusses hair regrowth using oral minoxidil 2.5mg and dutasteride 0.5mg, with some users reporting positive results. Others share their experiences with similar treatments, expressing hope for improvement and discussing side effects.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

User reports almost 2 months on DUT and MIN for hair loss with positive results. Treatment includes 0.5mg dut (morning), 5mg oral min (night), and vitamin D and B12 supplements.

The user is discussing hair regrowth after 7 months of using topical minoxidil and RU58841, with some microneedling. They are hesitant to switch to finasteride or dutasteride and are seeking input on whether there is new growth or just more miniaturization.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The conversation is about starting a hair loss treatment using a topical solution containing RU58841, Minoxidil, and Copper Peptides. The user plans to test the product and share updates on its effectiveness.